Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas

Xuesong Li200 enrolled

Overview

The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinoma (UTUC).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

200

Conditions

Upper Tract Urothelial Carcinoma Bladder Recurrence

Interventions

pharmorubicin or pirarubicinDRUG

pharmorubicin 50mg pirarubicin 30mg

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients who were clinically diagnosed with UTUC 2. Treated with radical nephroureterectomy Exclusion Criteria: 1. Distant metastasis 2. Prior history of bladder or synchronous bladder cancer 3. Administration of neoadjuvant chemotherapy 4. Presence of severe complications.

Outcomes

Primary Outcomes

intravesical recurrence-free survival

Time frame: two years after surgery

Secondary Outcomes

cancer-specific survival

Time frame: two years after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.